How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?
2005; BMJ; Volume: 331; Issue: 7520 Linguagem: Inglês
10.1136/bmj.331.7520.836
ISSN0959-8138
Autores Tópico(s)Cancer, Lipids, and Metabolism
Resumoselective serotonin reuptake inhibitors in 2003-5 and hormone replacement therapy in 2004. 3 4 In January 2005, the agency began to publish on the internet the summary data from the yellow card system for reporting adverse drug reactions as drug analysis prints (www.yellowcard.gov.uk/daps.html).It will consider legitimate applications for data on individual yellow card reports for research purposes, subject to ethical and scientific approval.In addition, from November 2005, the agency will start producing UK public assessment reports on each medicine that it licenses.These will provide details of the clinical trials submitted as part of the application.The agency has also established a communications division headed by a board level director.One of the division's main tasks is the wider dissemination of information about the work of the agency and the safety and efficacy of licensed medicines.Relationships between government, the health professions, and the public have evolved considerably in recent years.The setting up of the agency has been accompanied by wide ranging reviews of all aspects of medicines regulation.The changes now being implemented are intended to ensure that it continues to meet public expectations of scientific rigour, independence, and transparency in the years to come.Contributors and sources: AB and KW have both worked in academic clinical pharmacology and the NHS for many years and have considerable experience in medicines regulation.This
Referência(s)